ANIK
Anika Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $26 | $15 | -42% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $25 | $15 | -41% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $25 | $15 | -41% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $25 | $15 | -41% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $25 | $15 | -41% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $10 | $15 | +43% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q2 2026 | → $15 | -41% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Anika Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-259520Jun 5, 2026
- Form 40001193125-26-202704May 4, 2026
- Form 40001193125-26-197887Apr 30, 2026
- Form 40001193125-26-120005Mar 23, 2026
- Form 40001193125-26-111511Mar 17, 2026
- Form 40001193125-26-111502Mar 17, 2026
- Form 40001193125-26-111494Mar 17, 2026
- Form 40001193125-26-111492Mar 17, 2026
- Form 40001193125-26-102240Mar 11, 2026
- Form 40001193125-26-102239Mar 11, 2026
- Form 40001193125-26-102238Mar 11, 2026
- Form 40001193125-26-036129Feb 3, 2026
- Form 40001171843-25-004072Jun 24, 2025
- Form 40001171843-25-004071Jun 24, 2025
- Form 40001171843-25-004070Jun 24, 2025
Fundamentals
XBRL · Anika Therapeutics, Inc.Annual figures sourced directly from Anika Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Anika Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QFORM 10-QApr 30, 2026
- 8-KFORM 8-KApr 29, 2026
- DEF 14AProxy statementApr 28, 2026
- 10-KFORM 10-KMar 3, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 8, 2026
- 10-QFORM 10-QNov 5, 2025
- 8-KFORM 8-KNov 5, 2025
- 10-QFORM 10-QJul 30, 2025
- 8-KFORM 8-KJul 30, 2025
- 8-KFORM 8-KJul 30, 2025
- 8-KFORM 8-KJun 24, 2025
- 10-QFORM 10-QMay 9, 2025
- 8-KFORM 8-KMay 9, 2025
- DEF 14AProxy statementApr 28, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $10 | $15 | +43% |
| Two Sigma Investments | Q4 2025 | open | $9.99 | $15 | +50% |
| AQR Capital Management | Q2 2025 | open | $12 | $15 | +22% |
| Citadel Advisors | Q3 2024 | open | $25 | $15 | -41% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $25 | $12 | -52% |
| D.E. Shaw | Q3 2024 | open | $25 | $15 | -41% |
| AQR Capital Management | Q3 2024 | Q1 2025 | $25 | $18 | -29% |
| Millennium Management | Q3 2024 | Q2 2026 | $25 | $15 | -41% |
| Renaissance Technologies | Q3 2024 | open | $26 | $15 | -42% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.